Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: BMS Looks To Molecular Templates’ Engineered Toxin Bodies In Cancer

Executive Summary

Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity

You may also be interested in...



Sandoz Strikes $500m Deal For GSK Cephalosporins

Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.

Ensoma Launches With Takeda Partnership On Myeloablation-Free Gene Therapy

The company also raised a $70m Series A round and is looking to develop “off-the-shelf” gene therapies adapted to settings with fewer resources.

Avacta/Daewoong’s Joint-Venture AffyXell Paves Way For Next-Generation Stem Cell Therapy

A new joint venture from Avacta and Daewoong Pharmaceutical aims to use novel mesenchymal stem cells to secrete antibody mimetic "Affimers" to treat inflammatory diseases.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel